^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    thiotepa

    i
    Other names: DSP-1958
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    5d
    Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=31, Recruiting, Peking University People's Hospital | Phase classification: P4 --> P=N/A
    Phase classification
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan
    8d
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    9d
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • Neupogen (filgrastim) • Orencia (abatacept)
    9d
    Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial. (PubMed, Nat Med)
    Twenty-four newly diagnosed patients with GBM and unmethylated MGMT promoter were treated across eight cohorts following surgical resection and radiotherapy, testing Temferon doses ranging from 0.5 × 106 to 4.0 × 106 CD34+ cells kg-1 and different conditioning regimens (BCNU or busulfan, with or without thiotepa). Temferon is a safe and tolerable immunotherapeutic strategy in patients with newly diagnosed GBM. ClinicalTrials.gov: NCT03866109 .
    P1 data • Journal • First-in-human
    |
    CD34 (CD34 molecule)
    |
    thiotepa • busulfan • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
    23d
    A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=58, Completed, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Completed | Trial completion date: Jan 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    thiotepa
    23d
    Superior long-term survival with acceptable safety of ATG/G-CSF-based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS-AMKL. (PubMed, Front Oncol)
    Allo-HSCT in first complete remission (CR1) is recommended as the preferred strategy for improving survival, yet the benefit of BU/CY intensification with melphalan (MEL) or thiotepa (TT) remains unclear. In pediatric non-DS-AMKL, intensified conditioning (BU+MEL/TT) independently improved OS and LFS in patients transplanted in CR without increasing early NRM. Pre-transplant NR/PR status was the strongest adverse factor, markedly increasing RI and NRM, underscoring the importance of achieving remission before transplantation.
    Journal
    |
    CD34 (CD34 molecule)
    |
    melphalan • thiotepa
    24d
    SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma. (PubMed, Clin Lymphoma Myeloma Leuk)
    For fit patients, the current gold standard remains intensive induction with high-dose methotrexate (HD-MTX)-based polychemotherapy followed by thiotepa-conditioned autologous stem cell transplantation (ASCT)...Furthermore, evidence from international registries has shown promising activity of chimeric antigen receptor T (CAR-T) in relapsed/refractory patients, with acceptable toxicity. Looking ahead, the translation of circulating tumor DNA profiling "from bench to bedside" for measurable residual disease monitoring, alongside the integration of AI in radiomic assessment, and the introduction of personalized targeted approaches will further revolutionize the management of Primary Central Nervous System Lymphoma.
    Review • Journal • IO biomarker
    |
    IL10 (Interleukin 10)
    |
    methotrexate • thiotepa • methotrexate IV
    26d
    Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P4, N=31, Recruiting, Sun Yuqian
    New P4 trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan
    26d
    NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • methotrexate IV
    29d
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=66, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> May 2028 | Trial primary completion date: Nov 2027 --> May 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    1m
    A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    1m
    Cord Blood Transplantation in Children and Young Adults With Blood Cancer (clinicaltrials.gov)
    P2, N=71, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A)
    |
    cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • cyclosporine